![]() | |
Clinical data | |
---|---|
Trade names | Ecclock, Sofdra |
Other names | BBI-4000, BBI 4000 |
License data | |
Routes of administration | Topical |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H32BrNO5 |
Molar mass | 470.404 g·mol−1 |
3D model (JSmol) | |
| |
|
Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating).[1] It is an anticholinergic and is applied to the skin.[1]
It was approved in Japan in 2020, for the treatment of primary axillary hyperhidrosis.[2][3][4] It was approved for medical use in the United States in June 2024.[1][5]
Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.[1]
Sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands.[4] It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide,[6][7] meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.
Sofpironium bromide is the international nonproprietary name.[8]
It is marketed as Ecclock in Japan and as Sofdra in the US.